Alkermes plc has amended its previous deal to acquire Avadel Pharmaceuticals, raising the cash offer from $18.50 to $21.00 per share, with an additional contingent value right of $1.50 per share. This amendment was reported on November 18, 2025, and is expected to close in early 2026.